KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Gross Margin (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Gross Margin data on record, last reported at 37.11% in Q4 2025.

  • For Q4 2025, Gross Margin rose 1146.0% year-over-year to 37.11%; the TTM value through Dec 2025 reached 28.61%, up 440.0%, while the annual FY2025 figure was 28.61%, 440.0% up from the prior year.
  • Gross Margin reached 37.11% in Q4 2025 per PACB's latest filing, down from 41.36% in the prior quarter.
  • Across five years, Gross Margin topped out at 46.55% in Q4 2021 and bottomed at 3.69% in Q1 2025.
  • Average Gross Margin over 5 years is 32.18%, with a median of 34.8% recorded in 2025.
  • The widest YoY moves for Gross Margin: up 2044bps in 2025, down -3276bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 46.55% in 2021, then plummeted by -60bps to 18.79% in 2022, then dropped by -13bps to 16.4% in 2023, then skyrocketed by 56bps to 25.64% in 2024, then soared by 45bps to 37.11% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 37.11% in Q4 2025, 41.36% in Q3 2025, and 36.93% in Q2 2025.